Concepedia

Sarhad Alnajjar

SA

Statistics

Publications

4

Citations

131

H-Index

4

Active since

2017

Affiliations

Janssen (United States)(Current)

Janssen (Belgium)

Iowa State University

University of Surrey

Sarhad Alnajjar is an author at Janssen (United States) specializing in antiviral therapy, virology, and infectious diseases.

ORCID

Publications per year

2017–2024

4

Publications

4

Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor

Dirk Roymans, Sarhad Alnajjar, Michael B. Battles et al. · Nature Communications · 2017 · 97 citations · Full text

, , +17

Inhaled “Muco‐Trapping” Monoclonal Antibody Effectively Treats Established Respiratory Syncytial Virus (RSV) Infections

Morgan D. McSweeney, Sarhad Alnajjar, Alison Schaefer et al. · Advanced Science · 2024 · 13 citations · Full text

, , +14

JNJ-7184, a respiratory syncytial virus inhibitor targeting the connector domain of the viral polymerase

Brecht Bonneux, Afzaal Shareef, Sergey Tcherniuk et al. · Antiviral Research · 2024 · 11 citations · Full text

, , +17

Discovery of <i>gem</i>-Dimethyl-hydroxymethylpyridine Derivatives as Potent Non-nucleoside RSV Polymerase Inhibitors

Sandrine Grosse, Ludwig Cooymans, Werner Embrechts et al. · Journal of Medicinal Chemistry · 2024 · 10 citations

, , +17

1–4 of 4